Evolving concepts in the pathogenesis of multiple sclerosis and their therapeutic implications

Journal of Neuro-Ophthalmology

Volumn 21, Issue 4, 2001, Pages 279-283

  Rudick, R A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1 INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; NEUROPROTECTIVE AGENT;

CONFERENCE PAPER; DIAGNOSTIC IMAGING; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROOPHTHALMOLOGY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; REMISSION;

EID: 0035666699     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041327-200112000-00011     Document Type: Conference Paper

References (36)

1. Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis
2. MRI studies of multiple sclerosis: Implications for the natural history of the disease and for monitoring effectiveness of experimental therapies
3. Using gadoliniumenhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis
4. Multiple sclerosis: Histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy
5. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNβ-1a) for relapsing multiple sclerosis
6. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis
7. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A metaanalysis
8. Macrophage inflammatory protein 1-alpha mRNA expression in an immortalized microglial cell line and cortical astrocyte cultures
9. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis
10. A serial study of new MS lesions and the white matter from which they arise
11. Magnetic resonance spectroscopy: Imaging axonal damage in MS
12. Axonal transection in the lesions of multiple sclerosis
13. Axonal damage in acute multiple sclerosis lesions
14. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons
15. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin
16. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis
17. Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions
18. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy
19. High resolution proton NMR spectroscopy of multiple sclerosis lesions
20. In vivo localized NMR proton spectroscopy of normal appearing white matter in patients with multiple sclerosis
21. Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T
22. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis
23. 1H MRSI of normal appearing white matter in multiple sclerosis
24. Axonal dysfunction and disability in a relapse of multiple sclerosis: Longitudinal study of a patient
25. Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo
26. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis
27. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging
28. A longitudinal study of brain atrophy in relapsing multiple sclerosis
29. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing remitting MS
30. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease
31. Diversity and plasticity of self recognition during the development of multiple sclerosis
32. Neurodegeneration in multiple sclerosis: Relationship to neurologic disability
33. Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: Disease activity resumes after stopping treatment
34. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a
35. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability
36. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis